Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IACH MATH 2020 | Role of the gut microbiota in acute GvHD

Florent Malard • 8 Jun 2020
IACH MATH 2020
General

Florent Malard, MD, PhD, Saint-Antoine Hospital, Paris, France, speaks about the role of microbiota in acute graft-versus-host disease (GvHD). Prof. Malard reveals that fecal microbiota transplantation seems a promising treatment option for GvHD. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Florent Malard

Outcomes of a real-world comparison of standard-of-care ide-cel and cilta-cel in R/R myeloma
0:55
Outcomes of a real-world comparison of standard-of-care ide-cel and cilta-cel in R/R myeloma
Florent Malard • 24 Mar 2026
MaaT013 pooled allogeneic microbiotherapy in refractory GI acute GvHD: results of the ARES trial
1:50
MaaT013 pooled allogeneic microbiotherapy in refractory GI acute GvHD: results of the ARES trial
Florent Malard • 24 Mar 2026
Results of a survey investigating fertility and outcomes after CAR T-cell therapy
1:13
Results of a survey investigating fertility and outcomes after CAR T-cell therapy
Florent Malard • 7 Dec 2025
Results of ARES: allogeneic microbiotherapy for ruxolitinib-refractory GvHD with GI involvement
2:08
Results of ARES: allogeneic microbiotherapy for ruxolitinib-refractory GvHD with GI involvement
Florent Malard • 7 Dec 2025

Related Videos

From immunosuppression to targeted immunomodulation: emerging treatment strategies in GvHD
2:58
From immunosuppression to targeted immunomodulation: emerging treatment strategies in GvHD
Iskra Pusic • 11 Sep 2026
Three-year survival update of pre-induction azacitidine and venetoclax in newly diagnosed AML
3:46
Three-year survival update of pre-induction azacitidine and venetoclax in newly diagnosed AML
Maher Salamoon • 8 Sep 2026
Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy
2:01
Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy
Michael Jain • 11 Sep 2026
Long-term survivorship after CAR T-cell therapy: addressing non-relapse mortality
1:46
Long-term survivorship after CAR T-cell therapy: addressing non-relapse mortality
Michael Jain • 11 Sep 2026
The content of VJHemOnc is intended for healthcare professionals